Neonatal encephalopathy, particularly situations involving neonatal hypoxic–ischaemic encephalopathy (NHIE) and neonatal stroke (NS), covers complex neonatal conditions associated with a risk of neurodevelopmental difficulties. Early prevention programmes have shown benefits for neurodevelopment, but few address both NHIE and NS populations. Following an initial joint development phase with families and professionals, we identified two areas of intervention: (1) Making infant care and referral more streamlined and (2) Increasing parent empowerment. The PRevention and support for Parenthood in an early Rehabilitation programme is a multidisciplinary intervention initiated in the neonatal intensive care unit and continuing at home until the infant reaches a corrected age of 4 months. Its objectives are to: (1) Ensure that the family environment is adapted to the child’s needs, (2) Introduce parents to digital support suggesting information on the care pathway and developmental interventions, (3) Maintain continuity of care and (4) Maximise early detection by sharing videos for analysis of the child’s movements.

This longitudinal study uses a mixed-methods approach to assess the acceptability and feasibility of the early parenthood support programme involving parents and healthcare professionals. The qualitative research will be carried out through focus groups (parents and professionals) held at the end of the intervention programme. The corpus of semidirected collective interviews (focus group) will be processed by thematic content analysis. Initial coding and analysis will be conducted by the sociologist with expertise in qualitative methods, and the emerging themes and interpretations will then be discussed, refined and validated through interdisciplinary analysis meetings involving the broader research team. This collective analytical process will allow for deeper engagement with the data and ensure that interpretations are challenged and enriched by multiple professional perspectives. The quantitative research will rely on self-administered questionnaires (parents and professionals), assessment of child neurodevelopment using standardised tools by physiotherapists and assessment of parental skills using standardised observation grids.

This study has full approval from an independent ethics committee (CPP Ile de France I). Its findings will be published in peer-reviewed journals and conference presentations. The trial was registered on Clinicaltrials.gov (NCT05457569).

Although flow cytometric analysis of peripheral blood neutrophil myeloperoxidase expression can accurately rule out myelodysplastic neoplasms (MDS), it lacks reliability and efficiency due to the practical limitations of laboratory-developed liquid reagent-based assays. This study aimed to quantify the agreement and comparative discriminatory accuracy between a single-use flow cytometric lyophilised reagent tube (BD Lyotube Stain 468) and its laboratory-developed liquid reagent counterpart.

Cross-sectional diagnostic accuracy study of two index tests against a reference diagnosis.

A university hospital in France.

Consecutive adult patients with an indication for bone marrow aspiration due to suspected MDS and unexplained peripheral blood cytopenia.

MDS confirmed by cytomorphological evaluation of the bone marrow aspirate performed in duplicate by experienced haematopathologists blinded to the index test.

Of 103 participants enrolled between July 2020 and August 2021, 37 had MDS (prevalence, 36%). The median intra-individual robust coefficient of variation (RCV) for myeloperoxidase expression was 30.9% using the BD Lyotube Stain 468 and 31.2% using the laboratory-developed liquid reagent assay, with an intraclass correlation coefficient of 0.94 (95% CI 0.91 to 0.96). The areas under the receiver operating characteristic curves were 0.83 (95% CI 0.74 to 0.90) and 0.82 (95% CI 0.73 to 0.89), respectively. Using a prespecified threshold of 30.0%, the corresponding sensitivity estimates were 89% (95% CI 75% to 97%) and 95% (95% CI 82% to 99%).

BD Lyotube Stain 468 performs as well as its laboratory-developed liquid reagent counterpart for the quantification of myeloperoxidase expression by peripheral blood neutrophils. It may obviate the need for invasive bone marrow aspiration in up to 40% of patients with suspected MDS.

NCT04399018.